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The safety of oncolytic adenovirus-mediated suicide and inter-
leukin-12 (IL12) gene therapy was evaluated in metastatic
pancreatic cancer patients. In this phase I study, a replica-
tion-competent adenovirus (Ad5-yCD/mutTKSR39rep-hIL-12)
expressing yCD/mutTKSR39 (yeast cytidine deaminase/mutant
S39RHSV-1 thymidine kinase) and human IL-12 (IL12) was in-
jected into tumors of 12 subjects with metastatic pancreatic
cancer (T2N0M1-T4N1M1) at escalating doses (1  1011,
3  1011, or 1  1012 viral particles). Subjects received 5-fluo-
rocytosine (5-FC) therapy for 7 days followed by chemotherapy
(FOLFIRINOX or gemcitabine/albumin-bound paclitaxel)
starting 21 days after adenovirus injection. The study endpoint
was toxicity through day 21. Experimental endpoints included
measurements of serum IL12, interferon gamma (IFNG), and
CXCL10 to assess immune system activation. Peripheral blood
mononuclear cells and proliferation markers were analyzed by
flow cytometry. Twelve patients received Ad5-yCD/mutTKSR39-
rep-hIL-12 and oral 5-FC. Approximately 94% of the 121
adverse events observed were grade 1/2 requiring no medical
intervention. Ad5-yCD/mutTKSR39rep-hIL-12 DNA was de-
tected in the blood of two patients. Elevated serum IL12,
IFNG, and CXCL10 levels were detected in 42%, 75%, and
92% of subjects, respectively. Analysis of immune cell popula-
tions indicated activation after Ad5-yCD/mutTKSR39rep-hIL-
12 administration. The median survival of patients in the third
cohort is 18.1 (range, 3.5–20.0) months. The study maximum
tolerated dose (MTD) was not reached.
INTRODUCTION
According to the American Cancer Society, there will be an estimated
57,600 new cases of pancreatic cancer in 2020.1 Of those new cases,
approximately 50% will be diagnosed as advanced or metastatic dis-
ease. In 2020, pancreatic cancer will become the second leading cause
of cancer death, surpassing both breast and colorectal cancers.
Optimal pancreatic cancer treatments depend on the stage at diag-
nosis and include a combination of surgical resection, chemotherapy,
and/or radiation therapy. Even with the best treatments, the 5-year
overall survival rate for all stages of pancreatic adenocarcinoma is
9.3% and a dismal 2.9% for metastatic pancreatic cancer patients.2
For locally advanced, unresectable, or metastatic pancreatic cancer,
surgery is not always an option, and treatment goals include palliative
therapy to prolong survival as best as possible. Standard treatment op-
tions for these patients include systemic therapy with and without ra-
diation.3,4 For patients with good performance scores, FOLFIRINOX
(leucovorin, 5-fluorouracil [5-FU], irinotecan, oxaliplatin) or
gemcitabine + albumin-bound paclitaxel has become the standard
of care. However, even with these first-line therapies, the overall sur-
vival of metastatic pancreatic cancer patients is 11.1 and 6.8 months
for patients who received FOLFIRINOX and gemcitabine + albumin-
bound paclitaxel, respectively.5 Toxicities associated with FOLFIRI-
NOX limit its widespread application in patients with poor
performance status. Owing to the limited survival duration of patients
with metastatic pancreatic cancer, novel and alternative therapies are
desperately needed.
Oncolytic adenovirus-mediated cytotoxic gene therapy is an
approach developed and tested in several clinical studies. The onco-
lytic adenovirus delivers suicide genes to the target cells, which
convert pharmaceutical agents into toxic metabolites locally. The sui-
cide genes (yeast cytidine deaminase [yCD] and mutant S39R HSV-1
thymidine kinase [mutTKSR39]) have been evaluated in preclinical
models and used in clinical studies for prostate cancer.6–14 Long-
term survival data obtained in a previous clinical study suggested
that the oncolytic adenovirus-mediated cytotoxic gene therapy trig-
gered the immune system to target the tumor.15 We explored the
concept of combining our suicide gene therapy with a cytokine to pro-
mote the immune system activation against tumors. An oncolytic
adenovirus expressing the suicide genes and mouse interleukin-12
(mIL12) was constructed and tested in preclinical models.16 The
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injection of the newly constructed adenovirus into orthotopic tumors
resulted in the following: (1) increased levels of serum mIL12 and
interferon gamma (IFNG), and (2) increased numbers and activation
of natural killer (NK) cells and cytotoxic T lymphocytes. Tumor con-
trol in these preclinical models was improved with the combined sui-
cide gene therapy and IL12 immunotherapy. Based upon these
intriguing preclinical results, a new adenovirus was constructed ex-
pressing the human version of the IL12 gene (Ad5-yCD/mutTKSR39-
rep-human IL-12 [IL12]) for testing in the clinic.
A phase I dose-escalation clinical trial was conducted to assess the
safety of Ad5-yCD/mutTKSR39rep-hIL-12 in metastatic pancreatic
cancer patients. These patients received a single injection directly
into the pancreatic tumors of Ad5-yCD/mutTKSR39rep-hIL-12 at
one of three escalating doses. Patients subsequently received
standard-of-care chemotherapy at the discretion of the treating
oncologist. As was done in previous clinical trials, the persistence of
Ad5-yCD/mutTKSR39rep-hIL-12 DNA in the subjects’ blood was
followed. We also evaluated whether we could detect, using flow
cytometry, any activation of the immune system by assessing the
number of peripheral blood mononuclear cells (PBMCs) and a subset
of proliferation markers on those cells before and after treatment with
Ad5-yCD/mutTKSR39rep-hIL-12. Similarly, we investigated the levels
of serum IL12, INFG, and CXCL10 following Ad5-yCD/mutTKSR39-
rep-hIL-12 administration. Finally, we followed the survival of pa-
tients to assess the efficacy of the approach of combining oncolytic
adenovirus-mediated cytotoxic gene therapy and IL-12 cytokine ther-
apy with chemotherapy in patients with metastatic pancreatic cancer.
RESULTS
Patients and treatment
Between October 2017 and May 2019, 12 patients were enrolled
(Table 1). The median age of the patients enrolled in the study was
68 (range 55–84) years. Of the patients enrolled in the study, nine
were men and three were women; 10 patients were white and 2 Afri-
can American. Eastern Cooperative Oncology Group (ECOG) perfor-
mance scores ranged from 0 to 1. The median primary tumor dimen-
sions were 3.3 cm (range, 2.3–5.9 cm)  3.1 cm (2.0–4.3 cm) 
3.2 cm (1.5–5.1 cm). Tumor volumes ranged from 6 to 57 cubic cen-
timeters (cc) with a mean value of 22 cc as determined by computed
tomography (CT), magnetic resonance imaging (MRI), or endoscopic
ultrasound (EUS). Extra pancreatic extension or lymph node involve-
ment was observed in nine (75%) or seven (58%) of the patients,
respectively. Encasement of major blood vessels was reported in
four (25%) of the patients. Liver metastases were detected in all pa-
tients enrolled in the study. Other organs with potential metastases
included kidney, lung, spleen, and adrenal gland.
Median follow-up time of the surviving patients is 18.6 months. All pa-
tients enrolled in the trial received a single injection of adenovirus into
the pancreatic tumor mass at the prescribed dose listed in Table 1. All
patients received the prescribed dose of 5-fluorocytosine (5-FC) pro-
drugs according to protocol. Patients with good performance scores
were offered FOLFIRINOX for as many cycles as they could tolerate.
All but one patient in the current study received at least three cycles
of chemotherapy at the discretion of the treating oncologist. Six patients
in the current study started with FOLFIRINOX, while five received one
or more other chemotherapy options. One subject (patient 3) expired
after 1.6 months because of disease progression after the adenovirus
was injected and before chemotherapy could be administered. The
study design allowed for the endpoint to be reached (day 21) before
chemotherapywouldbegin to avoiddifficulty in the toxicity assessment.
Toxicity
Over 94% of the adverse events (AEs) regardless of their attribution
were mild (grade 1) or moderate (grade 2). The maximum tolerated
dose (MTD) was not achieved. A possible severe AE (SAE) observed
in one patient will be described in detail below. Treatment-related
AEs could be attributed to Ad5-yCD/mutTKSR39rep-hIL-12 (chills, fa-
tigue, flu-like symptoms, malaise, and increased serum alanine amino-
transferase/serum glutamic-pyruvic transaminase [ALT/SGPT] and
aspartate transferase/serum glutamic oxaloacetic transaminase [AST/
SGOT]) or the 5-FC prodrug therapy (anemia, diarrhea, nausea, vom-
iting, leukopenia, lymphopenia, and thrombocytopenia) (Table S1).
The incidence and severity of the AEs were nearly identical to those
observed in five previous clinical studies employing three similar onco-
lytic adenoviruses.9–14 A total of 121 AEs were recorded by the study
endpoint (day 21). Of the recorded 121 AEs, there were six grade 3
(5.0%) and one grade 4 (0.8%) toxicities, including one report of hypo-
tension, one episode of syncope, three incidents of hyperglycemia
(including one grade 4), an account of lymphopenia, and one resultant
spike in serum lipase. The reports of hypotension and syncope are
related and will be described below. Hyperglycemia can be attributed
to the underlying disease and comorbidities of the subjects. The grade
3 decrease in blood cell count is likely due to the 5-FC therapy and have
been observed in previous clinical trials using similar agents.9–14 The
reduced blood count returned to normal levels within 72 h without
intervention or modification of the study protocol.
The first subject (patient 7) in the third cohort, who received the high-
est dose of Ad5-yCD/mutTKSR39rep-hIL-12 (1  1012 viral particles
[vp]), experienced nausea, vomiting, and dizziness after taking the
first dose of 5-FC (Ancobon) medication on the morning of day 3
after adenovirus injection. Nausea and vomiting are common side
effects of the Ancobon treatment. Upon standing up from a seated po-
sition, the subject fainted, fell, and hit the back of her head on the wall
of the bathtub (grade 3 syncope). The subject was taken to the emer-
gency department by members of her family. Her diastolic blood
pressure (115/55 mmHg) was below normal range (grade 3 hypoten-
sion). She was administered fluids intravenously, and the laceration
on the back of her head was treated. The subject complained of head-
ache but denied chest pains or shortness of breath. She had a slight
fever (100.2F). Otherwise, there were no significant abnormalities
identified in blood chemistries. Resultant CT of the head and cervical
spine showed no fractures or acute traumatic injury. Chest X-rays did
not exhibit any etiology for her syncopal event. The subject was
admitted to the hospital for observation and supportive care and
was discharged the next day (day 4 from injection). She was seen twice
www.moleculartherapy.org
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Table 1. Clinical trial overview
Subject
1 2 3 4 5 6 7 8 9 10 11 12
Age (years) 56 68 77 74 69 58 84 68 72 66 55 66
Gender M M M M F M F M M M M F
Race W AA W W W W W W AA W W W
ECOG PS 1 1 0 1 0 1 0 0 0 1 1 0
Location of primary tumor B/N B H/N H/U T H B H T B/T B/T T
Primary tumor size (cc) 10 25 23 19 8 18 8 6 57 17 53 22
Extrapancreatic extension Y Y N Y Y Y N N Y Y Y Y
Lymph node involvement Y Y N Y N Y N Y N Y Y N
CA/SMA encasement N Y N N N N N N Y Y Y N
Liver metastases Y Y Y Y Y Y Y Y Y Y Y Y
Tumor in other organs N N kidney lung spleen lung N N Lu/Ki/Ad lung N N
Tumor stagea T2N1M1 T4N1M1 T2N0M1 T2N1M1 T2N0M1 T2N1M1 T2N0M1 T2N1M1 T4N0M1 T2N1M1 T4N1M1 T2N0M1
Cohort 1 1 1 2 2 2 3 3 3 3 3 3
Adenovirus dose (vp) 1  1011 1  1011 1  1011 3  1011 3  1011 3  1011 1  1012 1  1012 1  1012 1  1012 1  1012 1  1012
Chemotherapy regimen FOL G/A none G/A FOL to G/A FOL G G/A FOLFIRI FOL FOL FOLFIRI to FOLFOX to G/A
Status (as of 11/05/2020) expired expired expired expired expired expired expired alive expired alive alive alive
Number of grade >3 AEsb 1 1 0 3 0 1 1 0 0 0 0 0
Number of SAEsc 0 0 0 0 0 0 1 poss 0 0 0 0 0
Tumor response at 9 months PD PD ND SD SD PD SD SD PD SD PD PD
Survival (months)d 4.8 5.4 1.6 2.7 10.5 3.5 15.2 20.0 3.5 19.1 18.1 18.0
Adenovirus DNA in blood N N N N Y N Y N N N N N
IL-12/INF-g/IP10 in serum N/Y/Y N/Y/Y N/N/N Y/Y/Y Y/N/Y N/N/Y Y/Y/Y Y/Y/Y Y/Y/Y N/Y/Y N/Y/Y N/Y/Y
B, body; CA, celiac axis; CR, complete response; F, female; FOL, FOLFIRINOX; G, Gemzar; G/A, Gemzar/Abraxane; H, head; M, male; N, neck; ND, cannot be determined based on CT every 2–3 months; PD, progressive
disease; PR, partial response; SD, stable disease; SMA, superior mesenteric artery; T, tail; U, uncinate process.
aAmerican Joint Committee on Cancer, Eighth Edition.
bGrade R3 adverse events (AEs) through primary toxicity endpoint (day 21 after the adenovirus injection) and prior to the start of chemotherapy.
cSerious AEs (SAEs) that were unexpected and judged to be possibly/probably/definitely related to the investigational treatment (through day 21).






















































in a multidisciplinary pancreas cancer clinic the following week (days
5 and 8), and all symptoms, except for nausea, fatigue, and lighthead-
edness in the morning, had resolved. The subject resumed treatment
for her cancer on post-injection day 8. As per the study protocol, the
SAE was reported to the study Data SafetyMonitoring Board (DSMB)
for review. In addition to informing the DSMB, the institutional re-
view board (IRB) and US Food and Drug Administration (FDA)
were also notified of the SAE. No patients were enrolled in the study
during the DSMB review. One of the known side effects of IL12
administration is hypotension mediated by IFNG induction.17 Dur-
ing the DSMB review, the SAE can be designated as being unrelated
or possibly, probably, or definitely related to the study agent. The
DSMB determined that the SAE was possibly related to the study
agent in this case. In response to the DSMB assessment, the third
cohort was expanded from three patients to six patients and accrual
resumed. All five of the remaining patients in the highest cohort
completed their treatments and reached the endpoint without
encountering any SAE. Owing that only one of six patients (16%)
in the highest dose cohort developed a dose-limiting toxicity (DLT)
possibly related to the treatment, the study MTD was not reached.
Efficacy
Although the study is designed to evaluate the safety of combining
oncolytic adenovirus-mediated cytotoxic gene therapy and IL12
cytokine therapy with chemotherapy in patients with metastatic
pancreatic cancer, we also assessed the efficacy. The median survival
of subjects who were administered 1 1011 or 3 1011 vp Ad5-yCD/
mutTKSR39rep-hIL-12 had median survival durations of 4.8 (range,
1.6–5.4) and 3.5 (range, 2.7–10.5) months, respectively. All the pa-
tients who received these doses of Ad5-yCD/mutTKSR39rep-hIL-12
have expired. The two patients (patients 9 and 7) who received the
highest dose of adenovirus expired at 3.5 and 15.2 months, respec-
tively. At the time of writing this manuscript, four of the six patients
who received the highest dose of Ad5-yCD/mutTKSR39rep-hIL-12
(1  1012 vp) are still alive, with a median survival duration of 18.1
(range, 3.5–20.0) months. As part of routine follow-up, patients un-
dergo routine radiographic surveillance to assess disease progression.
With a median CT imaging follow-up after adenovirus injection of
16.8 (range, 16.1–17.4) months, two of the four surviving patients
were assessed to have stable disease in both the treated tumors
(pancreas) and the metastases found at other sites.
Experimental endpoints
In previous clinical trials, we have measured indirectly the persistence
of adenovirus DNA following intra-tumor injection by conducting
PCR on the subject’s blood. Persistence of adenovirus DNA in blood
more than a week after injection is evidence that the adenovirus is
replicating within the tumor where it is injected. The template
of the PCR primers is a sequence common to all of our related onco-
lytic adenovirus constructs and found specifically in Ad5-yCD/
mutTKSR39rep-hIL-12.
9 Post-injection day 14, Ad5-yCD/mutTKSR39-
rep-hIL-12 DNA was not detectable in any of the patients who
received the lowest dose (1  1011 vp) and was detectable in only
one subject (patient 5) who received 3  1011 vp (Figure 1).
It is of interest that adenovirus DNA was detectable in the one patient
from the second cohort who happened to be the longest survivor in
the first two cohorts (10.5 months post adenovirus injection). We
also detected Ad5-yCD/mutTKSR39rep-hIL-12 adenovirus DNA on
day 7 in only one patient of the highest adenovirus dose cohort
(patient 7). This is the patient who had the SAE described above
and survived 15.2 months past the adenovirus injection.
Immune response
To assess immune system activation, we measured serum IL12,
IFNG, and CXCL10 levels from blood post-adenovirus injection
relative to pre-adenovirus injection. In addition, IL12 expression
leads to IFNG production mainly by NK and natural killer T
(NKT) cells and activated CD4+ T cells and CD8+ cytotoxic
T cells.18 CXCL10 is secreted by monocytes, fibroblasts, and endo-
thelial cells in response to IFNG and possesses anti-angiogenic
properties.19,20 Blood was drawn within 30 days prior to adenovirus
injection (day 1) and then again on prescribed days after adenovirus
injection. Serum IL12 was not detected in the patients of the first
cohort (Table 2). In two of the second cohort patients, relatively
low levels of IL12 (1.1 and 11.3 pg/mL) were detected on day 21,
but none of the other time points. In the last cohort, serum IL12
was detected at relatively high levels (2.9–100.5 pg/mL) on at least
day 2 in three of six patients who received the highest dose (1 1012
vp). The serum IL12 through day 21 of the best responding patient
is shown in Figure 2A.
Figure 1. PCR of Ad5-yCD/mutTKSR39rep-hIL-12 DNA in blood
Positive control consisted of purified Ad5-yCD/mutTKSR39rep-hIL-12 DNA (1  104
vp) added to blood from a healthy volunteer. Pretreatment blood was drawn within
30 days of adenovirus injection. The day of each blood draw is indicated above the
indicated lanes. Negative control consisted of blood from a healthy volunteer with no
Ad5-yCD/mutTKSR39rep-hIL-12 DNA added. PCR data from patients 5 and 7 are
shown in the top and bottom panels, respectively.
www.moleculartherapy.org
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Serum IFNGwas detected in 9 of 12 subjects, including two of three in
cohort 1, one of three in cohort 2, and all six patients of cohort 3
(Table 2). In most of the patients, the peak detected serum IFNG
was detected at the earliest time point (day 2 or 3). Subjects 1 and 4
had peak IFN-g on day 14, and patient 10 had elevated IFNG on
day 21. Peak serum IFNG concentrations (relative to pretreatment
levels) ranged from 41.8 to 561.0 pg/mL. As with IL12, the highest
serum concentration of IFNG was observed in patient 7 (Figure 2B).
In all patients, serum CXCL10 peaked at earliest time point and then
dropped in subsequent measurements. Interestingly, the concentra-
tion of CXCL10 at the earliest time point after adenovirus injection
appears to be related to the adenovirus dose. The average CXCL10
concentrations of cohorts 1, 2, and 3 were 786.1 (range 672.9–
899.3), 904.1 (447.1–1,203.8), and 4,266.4 (1,302.8–6,971.9) pg/mL,
respectively (Table 2). Serum CXCL10 was highest (6,971.9 pg/mL)
and persisted the longest (detected on days 2, 4, 7, 14, and 21) in pa-
tient 7 (Figure 2C).
Serum NK/CD4+/CD8+ cell populations
Circulating PBMCs were analyzed by flow cytometry as a measure of
immune system activation. Except for one patient, blood was drawn
once prior to adenovirus injection (baseline) and then on indicated
days post adenovirus injection (adenovirus injection on day 1). There
was no preinjection blood draw obtained for patient 2 (cohort 1).
Frozen PBMCs from each patient were thawed, stained with antibody,
and analyzed by flow cytometry. Specific antibodies to CD3, CD56,
CD4, and CD8 were used to segregate and count immune cell popula-
tions (e.g., NK, T helper, and T cytolytic cells). Antibodies were used
against CD45(RO), CD69, Ki67 and Tim3. The first threemarkers indi-
cate that the immune system was activated following treatment. Tim3
is an immune checkpoint protein and indicates that the immune sys-
tem was supressed following treatment.21–23 CD45RO is a maturation
marker, whereas CD69 and Ki67 indicate immune cell activation and
proliferation, respectively. The data were reported as fold increase
over the pretreatment blood draw for each cohort. More cells found
in subjects’ blood after adenovirus injection than before were positive
for markers indicating matured, activated, or proliferating immune
cells. For example, on day 7 post adenovirus injection, there was a
nearly 3-fold increase in the number of CD3CD56+ NK cells express-
ing the proliferation marker Ki67 in cohort 1 (Figure 3A). In cohorts 2
and 3, there were 8-fold increases in the number of NK cells expressing
Ki67 on day 7, respectively (Figures 3D and 3G).
Increased numbers of cells expressing Ki67 were observed also in
CD3+CD4+ T helper cells (Figures 3B, 3E, and 3H); in cohort 2, the
level of CD3+CD4+ cells expressing Ki67 persisted through day 21
(Figure 3E). Ki67 expression in CD3+CD8+ T cells also increased
over pretreatment levels (Figures 3C, 3F, and 3I). These changes in
Ki67 expression indicate that the immune system was activated
following adenovirus injection into the pancreatic tumors. Another
indication in the activation of the immune system was observed in
the increase in the number of cells that expressed CD69, which
following immune system activation is one of the earliest inducible
lymphoid cell surface glycoproteins.22 The increases in the counts
of cells expressing CD69 that was observed in many of the cell pop-
ulations did not appear to be dependent upon the dose of adenovirus
(Figure 3). CD45RO expression is associated with activated and
CD3+CD8+ T cytolytic memory cells. Of note, we observed in cohort
3 that CD3+CD8+ T cells showed an initial increase in the number of
cells expressing CD45RO, but then by day 21, the number of cells re-
turned nearly to baseline (Figure 3I). This observation is consistent
with the “On-Off-On” model for memory T cells.26 In this model,
T cells are activated when the T cell receptor binds to an antigen,
causing the cell to turn “On” and proliferate. After the antigen is
cleared, these cells are turned “Off,” and some circulate through the
body as T memory cells. When the specified antigen is encountered
again, these cells are turned “On” and mount an effective response af-
ter reactivation. Finally, it is of interest that the number of CD3+CD8+
T cells expressing the immune checkpoint, Tim3, increased over time
relative to pretreatment levels in cohort 1 (Figure 3C). In contrast, the
number of CD3+CD8+ T cells in cohorts 2 and 3 expressing Tim3
largely stays at near pretreatment levels or even decreased over time
(Figures 3F and 3I). Tim3 plays a role in CD3+CD8+ T cell exhaus-
tion.23–25
DISCUSSION
The primary endpoint of the study was to determine the tolerability
and MTD of oncolytic adenovirus-mediated suicide and IL12
gene therapy and prodrugs in metastatic pancreatic cancer
patients. Ad5-yCD/mutTKSR39rep-hIL-12 doses were escalated from
1  1011 to 1  1012 vp in three half-log steps followed by 7 days
of 5-FC prodrug therapy starting on day 2 and then chemotherapy
starting 21 days after adenovirus injection. Like other clinical trials
using similar oncolytic adenovirus agents, over 90% of the AEs
observed in this trial were grade 1 or 2 and required no medical inter-
vention to resolve. In the present study, an SAE possibly related to the
study agent was encountered in one subject of the third cohort.
Consequently, the third cohort was expanded to include six patients
Table 2. Peak serum cytokine day and concentrations
Cohort no. Patient no.
IL12 INFG CXCL10
Day pg/mL Day pg/mL Day pg/mL
1
1 not detected 14 88.1 2 672.9
2 not detected 3 41.8 3 899.3
3 not detected not detected not detected
2
4 21 1.1 14 51.6 2 1,203.8
5 21 11.3 not detected 2 1,061.3
6 not detected not detected 2 447.1
3
7 2 100.5 2 561.0 2 6,971.9
8 2 2.9 2 45.5 2 2,564.6
9 2 23.1 2 193.3 2 3,830.1
10 not detected 21 75.6 2 1,302.8
11 not detected 3 91.1 3 5,690.1
12 not detected 2 165.7 2 5,239.1
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according to protocol. No other SAEs were encountered, hence the
MTD was not reached. The study demonstrates that intra-pancreatic
administration of Ad5-yCD/mutTKSR39rep-hIL-12 followed by 5-FC
prodrug therapy and chemotherapy is safe.
We have completed five phase I clinical trials and one prospective,
randomized, controlled phase I/II clinical trial using three similar
oncolytic adenoviruses in newly diagnosed and locally recurrent
prostate cancer.9–14 Colleagues have completed a phase I clinical
trial in locally advanced pancreatic cancer patients using a similar
adenovirus construct, Ad5-yCD/mutTKSR39rep-ADP. They re-
ported that the combination of the oncolytic adenovirus-mediated
gene therapy combined with gemcitabine was well tolerated in
this population of patients.27 The median progression-free survival
was reported to be 11.4 months. In addition, we have recently
completed a phase I trial using Ad5-yCD/mutTKSR39rep-hIL-12 in
locally recurrent prostate cancer patients (unpublished data: K Bar-
ton, F Siddiqui, S Freytag, and B Movsas). Although there are many
similarities with the current clinical trial and the others mentioned,
the present study is the first to include the following: (1) use of IL12
immuno-gene therapy in combination with our oncolytic adeno-
virus suicide gene therapy, and (2) use of our therapeutic approach
in metastatic (pancreatic) disease.
IL12 therapy (including IL12 gene therapy) has been employed in
several phase I clinical studies for cancer with mixed results.28 The
underlying interest in IL12-mediated tumor immunotherapy is based
upon its well-characterized ability to activate both the innate and
adaptive arms of the immune system. Under ideal situations, IL12
expression by professional antigen-presenting cells acts on NK,
CD4+, and CD8+ cells, causing them to produce IFNG and eventually
CXCL10, both of which have many antitumor activities and promote
coordinated antitumor immunity.19,20 In prior clinical applications,
however, IL12-mediated tumor immunotherapy has not demon-
strated significant efficacy and instead, there were cases of unaccept-
able toxicities with this approach. Additionally, severe side effects,
including deaths of study patients, often have been associated with
systemic administration of IL12. Targeted or tumor-specific expres-
sion of IL12 appears to provide the benefits of IL12-mediated tumor
immunotherapy with less of the toxicity observed with systemic
administration.18 This is the approach we employed by engineering
our oncolytic adenovirus that expresses the suicide fusion genes
yCD/mutTKSR39 and Ad5-yCD/mutTKSR39rep-hIL-12 to also express
the hIL-12 gene.16 One of the benefits of using an oncolytic adeno-
virus is its ability to convert “immunologically cold” tumors into
“immunologically hot” tumors. Cold tumors are characterized by
having low levels of immune cell populations, whereas immune cells
are present in hot tumors.
Others have argued that low mutational burden is of equal impor-
tance as lack of immune cells in the definition of “immunologically
cold” tumors.29 Mutation burden is the property of the tumor genome
that results in novel DNA sequences leading to novel polypeptide se-
quences presented on tumor cells. These novel polypeptides act as
neoantigens for the immune system to recognize and target tumor
cells for destruction. The combination of these two characteristics
(absence of immune cells and lowmutation burden) in a tumor limits
the ability of the immune system to act on a tumor. Pancreatic tumors
are characterized as cold tumors because there is often an absence of
immune cells in the tumor and the low mutation burden. Our
approach of oncolytic adenovirus-mediated suicide and IL12 gene
therapy in combination with chemotherapy could attract immune
cells into the tumor, thereby reversing the normal situation found
in pancreatic cancers (i.e., absence of immune cells). It is likely that
the immune cells attracted to the tumor following Ad5-yCD/
mutTKSR39rep-hIL-12 treatment are actually targeting the adeno-
virus, or more likely the cells infected with the adenovirus. We also
observed in these patients the temporary increases in serum cytokines
(such as IL12, IFNG, and CXCL10) in response to adenovirus injec-
tion. Likewise, following Ad5-yCD/mutTKSR39rep-hIL-12 injection,
we observed in many patients increased PBMCs and a subset of pro-
liferation markers on those cells. At 12 months post-adenovirus
Figure 2. Serum IL12gamma, IFNG, and CXCL10 levels in patient 7
Blood was drawn on the day of adenovirus injection prior to the procedure (day 1) and
then on the indicated days (2, 4, 7, 14, and 21). Cytokine measurements were made
by ELISA using a standard curve specific for each cytokine (0–1,000 pg/mL). Panels A
and B show serum IL12 and IFNG, respectively. For CXCL10, the patient samples
were diluted 1:100, panel C. Concentration of each cytokine is listed in pg/mL.
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injection, two of six patients who received 1  1012 vp (highest dose)
of Ad5-yCD/mutTKSR39rep-hIL-12 and completed the 5-FC prodrug
therapy and several rounds of chemotherapy have stable disease,
not only in the treated tumors but also the metastatic lesions
found in liver and lung. Patients 7 and 8 received gemcitabine or
gemcitabine/protein-bound paclitaxel (Abraxane), respectively, after
adenovirus and 5-FC therapies. The progression-free survivals of
patients 7 and 8 were 11.5 and 16.1 months, compared with a
median expected duration of 3.3 months for gemcitabine-treated
patients. Likewise, their overall survival durations were 15.2 and
20.0 months compared with an expected 6.4 months for gemcitabine
alone. No conclusions can be made from these data, but hypotheses
regarding the current situation of their disease can be formulated
(see below).
A second novel aspect of this study is that metastatic pancreatic pa-
tients were treated with the oncolytic adenovirus-mediated suicide
and IL12 gene therapy. In previous studies, patients with newly diag-
nosed or locally recurrent disease were enrolled. In fact, evidence of
disseminated disease was an exclusion criterion in our previous trials.
All patients in this trial, by contrast, had disseminated disease. This
presented both a potential hazard and an opportunity. The hazard
would be that in a study where one tumor was treated and other tu-
mors were not, then the untreated tumors may progress and obscure
both the toxicity and efficacy data of the study agent that could have
been obtained. The opportunity would be realized if the study agent
would result in the development of antitumor immunity, which
would lead to effects in the disseminated tumors found in the liver
and lungs. It appears that the latter case may have happened in the
patients in cohort 3. All surviving patients have had at least one
follow-up CT assessment to evaluate tumor response. The median
follow-up for CT assessments is 16.0 months. In two cases, the pri-
mary or treated tumors and metastatic tumors (untreated) were sta-
ble. The median progression-free survival for cohort 3 is 10.6 (range,
2.2–17.4) months. For comparison, the median progression-free
survival time of metastatic pancreatic cancer patients who receive
FOLFIRINOX or gemcitabine alone was 6.4 or 3.3 months,
respectively.5
Although encouraging signs of efficacy were observed in the subjects
who received the highest dose of Ad5-yCD/mutTKSR39rep-hIL-12, no
conclusions regarding efficacy can be drawn from a phase I study.
However, hypotheses can be generated, which then can be the basis
for future clinical studies. For example, because the MTD was not
reached, it is uncertain whether Ad5-yCD/mutTKSR39rep-hIL-12
can be administered at higher doses (e.g., 3  1012 vp). The efficacy
Figure 3. Peripheral blood mononuclear cell (PBMC) counts and markers
Blood was drawn pre- and post-adenovirus injection (day 1). PBMCs were harvested and frozen from each patient. Cells were thawed; stained with antibodies against CD3,
CD56, CD4, CD8, CD69, CD45(RO), Ki67, and Tim3; and subjected to flow cytometry. All data are reported as group mean fold-increase over baseline blood collected prior
to adenovirus injection, which occurred on day 1. Error bars show standard deviation. Day 21 data for cohort 1 were limited to patient 1 only. Samples from cohort 1 are
shown in panels A-C; cohort 2 in panels D-F; and cohort 3 in panels G-I.
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data reported here indicate that dose escalation may be warranted.
However, rather than conduct a simple phase I/II dose-escalation trial
to determine the MTD, conducting a continuous reassessment
method (CRM) phase I/II study might be a better use of resources
and effort. The CRM would facilitate potentially a rapid determina-
tion of the MTD through the phase I dose escalation to maximize
the number of patients treated at or near the MTD for the phase II
component of the trial. The study design of this proposed study would
be like the current study in that chemotherapy would be combined
with the oncolytic adenovirus-mediated suicide and IL12 gene ther-
apy in patients with metastatic pancreatic cancer.
Pancreas tumors are characterized by having variable levels of inter-
stitial pressure and fibrosis secondary to a dense tumor stroma. These
characteristics when present at high levels may limit the effectiveness
of injecting adenovirus into pancreatic tumors as a result of leakage
from the injection site or reduced adenovirus absorption or transduc-
tion of the tumor itself. The variable nature of the pancreatic tumor
microenvironment may partially explain why some patients in the
higher dose cohort responded worse than others. A method to assess
or image the quality of the adenovirus injection may be helpful in
future clinical studies. Ad5-yCD/mutTKSR39rep-hIL-12 expresses
mutTKSR39, the activity of which can be imaged non-invasively us-
ing positron emission tomography (PET) using a thymidine kinase
substrate, 9-(4-[18F] fluoro-3-hydroxymethylbutyl guanine) ([18F]-
FHBG). Following intravenous injection of [18F]-FHBG, the thymi-
dine kinase substrate would be concentrated in cells infected with
Ad5-yCD/mutTKSR39rep-hIL-12 and could be imaged non-invasively
using PET. PET imaging is quantitative and would allow us to assess
the efficacy of Ad5-yCD/mutTKSR39rep-hIL-12 injections into the
pancreas. We have demonstrated the feasibility of imaging an adeno-
virus expressing thymidine kinase injected into the pancreas of a
canine preclinical model.30
Regardless of the next clinical study using Ad5-yCD/mutTKSR39rep-
hIL-12, the experiences of this clinical study should inform the
design of future studies. For example, hypotension has been noted
as an adverse effect of IL12 plasmid or gene therapy.31 High vigi-
lance of AEs such as hypotension related to IL12 therapy is recom-
mended, including a suggestion to clinicians to urge caution with
patients who are on hypertension medicine while receiving Ad5-
yCD/mutTKSR39rep-hIL-12. Other AEs associated with IL12 ther-
apy include flu-like symptoms and hematological complications,
such as neutropenia and thrombocytopenia. One of the known
side effects of suicide gene therapy in our experience is depression
of blood cell counts (i.e., neutropenia and thrombocytopenia).18
Hence there is a possible combined effect of IL12 and the suicide
genes on depressing blood cell counts. The administration of onco-
lytic adenovirus constructs can result in flu-like symptoms, which
can be exacerbated by IL12. The designers of a future dose-escala-
tion study involving suicide and IL12 gene therapy should be aware
of these potential complications. Considering the one SAE possibly
related to the study agent, the safety profile of Ad5-yCD/mutTKSR39-
rep-hIL-12 is considered acceptable and similar in safety profile to
the three other oncolytic adenovirus constructs that we have as-
sessed in clinical studies.
MATERIALS AND METHODS
Study design
This was an IRB-approved phase I dose-escalation study designed to
evaluate the safety of the replication-competent adenovirus, Ad5-
yCD/mutTKSR39rep-hIL-12. The patient population consisted of met-
astatic pancreatic adenocarcinoma patients. Primary endpoints
included determining the MTD and DLTs of the study agent up to
day 21 post adenovirus injection. The secondary endpoint included
rates of grade 3 AEs using the National Cancer Institute’s (NCI’s)
Common Terminology Criteria for AEs version 4.03 (CTCAE
v.4.03). Exploratory endpoints included possible association between
primary/secondary outcomes and the following: (1) serum hIL-12,
IFNG, and CXCL10 levels; (2) circulating CD3CD56+ NK,
CD3+CD4+ T helper cells, or CD3+CD8+ T cells; and (3) expression
of a subset of proliferation markers (e.g., CD69, CD56, and Ki67)
and a checkpoint marker (Tim3) on the serum NK and T cell popu-
lations. An independent DSMB supervised all aspects of the study,
including the collection and review of all toxicity data.
There were three doses of adenovirus injected in this trial (1  1011,
3 1011, and 1 1012 vp). Each member of the three patient cohorts
received a single dose of adenovirus injected directly into the pancre-
atic tumors (details below). In the event of a DLT (defined below), the
cohort would be expanded from three to six patients. If a second DLT
would be observed (DLT observed in 33% of the patients of the
expanded cohort), then the next lower dose cohort would be
expanded to six patients. If the R33% of the patients in the first
cohort had developed a DLT, then the trial would have been
terminated.
A DLT was defined as any toxicity (possibly, probably, or definitely)
related to the investigational agent (Ad5-yCD/mutTKSR39rep-hIL-12)
that results in any of the following outcomes: gradeR3 allergic reac-
tion or generalized urticaria, gradeR3 cardiovascular or neurological
toxicity, and grade R3 hematologic or non-hematologic toxicity of
any duration (except for grade 3/4 lymphopenia recovered within
2 weeks; grade 3/4 anemia, leukopenia, neutropenia, or flu-like symp-
toms that are reversible within 72 h; grade 3 SGOT/SGPT serum
levels that are reversible with 72 h; grade 3/4 hyperglycemia that
can be explained by patient’s baseline comorbidity [e.g., diabetes];
and grade 3/4 electrolyte imbalances that are reversible within 72 h).
Eligibility criteria included histologically proven (biopsy or cytology)
metastatic pancreatic adenocarcinoma in patients R18 years old. No
prior treatment, including surgery, chemotherapy, radiotherapy, or
biological therapy, for pancreatic cancer was allowed. Zubrod perfor-
mance score of 0–2 within 30 days of registration was required.
Adequate baseline organ functions were required within 30 days of
registration. Laboratory values required for enrollment included serum
creatinine %1.8 mg/dL or creatinine clearance >50 mL/min/m2,
platelet count >100,000/mL, absolute neutrophil count >1,000/mL,
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hemoglobin >8.0 g/dL, bilirubin >2.0 mg/dL, and AST/SGOT and
ALT/SGPT <3.0 times upper limit of normal (ULN). The AST/
SGOT and ALT/SGPT requirements were relaxed to <5.0 times ULN
for patients with liver metastases.
Women of childbearing age andmale participants agreed to use medi-
cally effective means of birth control throughout and for 60 days
beyond the treatment phase of the study. Patients on anticoagulation
therapies were monitored for signs or symptoms of bleeding. Subjects
were required to possess the ability to provide informed consent and
express a willingness to meet all expected requirements for the proto-
col for the duration of the study.
Exclusion criteria included any of the following: pregnant or lactating
women, clinical or laboratory evidence of pancreatitis based upon the
discretion of the treating physician, a serious non-malignant disease
(e.g., congestive heart failure or uncontrolled infections) that at the
discretion of the treating physician would compromise study objec-
tives, and major surgery within 3 months of study registration. Pa-
tients presenting with non-adenocarcinoma of the pancreas (e.g., islet
cell tumor, such as neuroendocrine tumors, cystic neoplasms, or peri-
ampullary carcinoma) were excluded. The presence of an acute infec-
tion defined as any viral, bacterial, or fungal infection that required
specific therapy within 72 h of study initiation, previous history of
liver disease (including hepatitis), positive serological tests for hepa-
titis B or C at baseline, immunosuppressive therapy including sys-
temic corticosteroids, impaired immunity or susceptibility to serious
virus infections, an allergy to any product used in this study, or
serious medical or psychiatric illness or concomitant medication
that might interfere with the subject’s ability to tolerate or complete
the study were also exclusionary criteria. The trial was registered on
the NIH National Library of Medicine database (https://www.
clinicaltrials.gov/) with the NTC registration code ClinicalTriagls.gov:
NCT03281382.
Design and manufacturing of Ad5-yCD/mutTKSR39rep-hIL-12
adenovirus
The design of Ad5-yCD/mutTKSR39rep-hIL-12 adenovirus was con-
structed using techniques such as those used previously.16 In brief,
the left-end vector containing the yCD/mutTKSR39 fusion gene
cassette under transcriptional control of a human cytomegalovirus
(CMV) promoter has been described previously.8 The source for
hIL-12 was pUNO1-IL-12 (p40::p35) (InvivoGen, San Diego, CA,
USA). The 1,611-bp encoding sequence was amplified by PCR and
cloned between a CMV promoter and SV40 polyadenylation sites
of pCA14 (Microbix, Mississauga, ON, Canada). The CMV-hIL-12-
SV40 expression cassette was cloned into pBGH8k at the SwaI and
PacI endonuclease sites. The adenovirus was generated by calcium
phosphate precipitation of the pCA14-yCD/mutTKSR39 and
pBGH8k-hIL-12 plasmids linearized with PvuI and ClaI, respectively.
The precipitated DNA was co-transfected in AD293 cells and then
purified (Adenopure; Puresyn, Malvern, PA, USA). DNA sequencing
was used to verify sequences of the suicide genes and hIL-12. The
cytopathic properties of the Ad5-yCD/mutTKSR39rep-hIL-12 adeno-
virus were tested in several different cell lines. Clinical-grade (Good
Manufacturing Process [GMP]) Ad5-yCD/mutTKSR39rep-hIL-12
adenovirus was made at the Baylor College of Medicine Gene Vector
Laboratory (Houston, TX, USA). A Master Viral Bank was generated
and tested for safety, sterility, titer, endotoxin, identity (PCR and
DNA sequencing), transgene expression, and potency, as described
by Freytag et al.9 All safety tests were negative. All identity and po-
tency tests were similar to the laboratory-grade stock adenovirus.
The stock concentration of the adenovirus was 1.0  1012 vp/mL
and supplied in a clear, frozen liquid in individual vials of 1.1 mL.
Each vial was labeled serially. One vial would be thawed, and the
appropriate amount of adenovirus stock solution would be diluted
for each patient (see details below).
Treatment
Informed consent was obtained prior to study-related procedures be-
ing performed. Under conscious sedation (combination of meperi-
dine and midazolam or propofol), a linear echoendoscope was in-
serted into the patient’s stomach or duodenum under direct
visualization. The dimensions of the pancreas and the adenocarci-
noma mass were acquired using the echoendoscope. The study agent
(Ad5-yCD/mutTKSR39rep-hIL-12 + phosphate-buffered saline [PBS])
would be prepared so that the total injection volume was 10% of the
tumor mass. Under direct ultrasonographic visualization, a 22GWil-
son-Cooke Echotip needle was inserted into the tumor through the
safest approach (trans-gastric or -duodenal) as determined by the in-
terventional gastroenterologist. The gastric approach was the prefer-
ential choice to reduce the risk for duodenal perforation. The needle
tip was placed at the distal edge of the tumor (relative to needle entry
site), and the study agent was injected along the tract as the needle was
withdrawn. Multiple needle passes were required for larger tumors to
provide good coverage. Forty-eight hours postprocedure, patients
received a 7-day course of 5-FC (150 mg/kg/day, 4 times a day orally;
Ancobon). Patient compliance was monitored by the study nurse.
Twenty-one days after adenovirus injection, patients began to receive
standard-of-care systemic therapy at the discretion of the treating
physician. The preferred therapies were FOLFIRINOX (5-FU, leuco-
vorin, irinotecan, oxaliplatin) or Gemzar/Abraxane (gemcitabine +
albumin-bound paclitaxel). Cycles of the preferred therapies were
continued until the patient’s death or at the discretion of the treating
oncologist when considering toxicities resulting from the chemo-
therapy regimen. Other/secondary options for chemotherapy would
be implemented as determined by the treating physician.
Assessments
Toxicity assessments were performed once a week prior to the start of
chemotherapy (first 3 weeks) and then at scheduled follow-up visits at
3, 6, 9, 12, 18, and 24 months. Toxicities were graded using the
CTCAE v.4.03. Case report forms (CRFs) specifically designed for
this trial were used to document AEs.
Evaluations prior to the start of chemotherapy (day 21) included
complete weekly blood counts; blood chemistries; comprehensive
metabolic panel; presence of Ad5-yCD/mutTKSR39rep-hIL-12 viral
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DNA and infectious adenovirus in blood, serum IL12, IFNG, and
CXCL10; and physician assessment. Evaluations during chemo-
therapy were monitored according to standard of care for patients
receiving chemotherapy or as clinically indicated and included com-
plete blood counts; blood chemistries; presence of Ad5-yCD/
mutTKSR39rep-hIL-12 viral DNA and infectious adenovirus in blood,
serum IL12, IFNG, and CXCL10; CA19-9 according to standard of
care for subjects receiving chemotherapy or as clinically indicated;
and provider assessments. Chemotherapy clinical follow-up assess-
ments occurred according to standard of care for metastatic pancre-
atic cancer patients receiving chemotherapy or as clinically indicated.
These evaluations included patient history; physical examinations;
performance status; complete blood counts; blood chemistries; pres-
ence of Ad5-yCD/mutTKSR39rep-hIL-12 viral DNA, serum IL12,
IFNG, and CXCL10; CA19-9; CT scans (pancreas and chest protocols
every 2 months); and toxicity assessments at every scheduled follow-
up visit using CRFs designed for this trial. Notably, the presence of
Ad5-yCD/mutTKSR39rep-hIL-12 viral DNA in blood, serum IL12,
IFNG, and CXCL10 levels were monitored at every blood draw until
not detected in two consecutive measurements.
Administration of 5-FC
5-FC (Ancobon; Roche Laboratories, Basel, Switzerland) was admin-
istered orally beginning day 3 post injection and continued for 7
consecutive days. A total of 150 mg/kg/day was given.
PCR of Ad5-yCD/mutTKSR39rep-hIL-12 adenoviral DNA in blood
The assessment of adenovirus DNA in subjects’ blood has been
described previously.9 In brief, blood was obtained before the adeno-
virus was injected to obtain a baseline value for each patient. Then
blood was drawn at prescribed time points following adenovirus in-
jection to assess the level of serum Ad5-yCD/mutTKSR39rep-hIL-12
adenovirus DNA. The PCR primers hybridize the linker located be-
tween the yCD and the mutant HSV-1 TK gene. The PCR product
is 388 bases in length and specific for the yCD/mutTKSR39 fusion
gene. To generate a standard curve, human volunteer blood was
spiked with Ad5-yCD/mutTKSR39rep-hIL-12 adenovirus DNA from
50 vp/mL to 5.0  109 vp/mL serial dilutions. The sensitivity of the
assay is 50 vp/mL.
Flow cytometry
Blood was drawn once pretreatment (days30 to1) and then again
on days +3, +7, +14, and +21 to isolate PBMCs, which were stored in
liquid nitrogen until analysis. The PBMC freezing media consisted of
10% dimethylsulfoxide (DMSO) and 90% heat-inactivated fetal
bovine serum. PBMCs were quickly thawed in a 37C H2O bath,
then washed once in room temperature 1X PBS and centrifuged at
1,500 rpm for 10 min at 4C. Supernatants were removed, and
contaminating red cells were lysed, while the remaining mononuclear
cells were fixed at room temperature, for 10 min, in FACSLyse solu-
tion (BD Biosciences, San Jose, CA, USA). Cells were pelleted by
centrifugation at 1,500 rpm at 4C for 10 min. After supernatant
removal, the cells were resuspended in wash buffer (1X PBS, 5%
bovine serum albumin, 10% sodium azide), then aliquoted to labeled
wells of a Falcon 96-well round-bottom tissue culture plate (Corning,
Durham, NC, USA). Plated cells were centrifuged at 1,500 rpm for
5 min at 4C; then the supernatants were removed without dislodging
the pellets. Cells were blocked by incubation in FC block (BioLegend,
San Diego, CA, USA) at room temperature for 10 min. Following pre-
blocking, plated cells were centrifuged, as above, and the cells were
incubated in the dark at room temperature for 30 min with a cocktail
of antibodies to surface antigens containing anti-human CD3 conju-
gated with allophycocyanin-Cy7 (APC-Cy7), anti-human CD56
conjugated with PEDazzle 594, anti-human CD45RO conjugated
with R-phycoerythrin-Cy7 (PE-Cy7), anti-human CD8 conjugated
with BV510, anti-human CD69 conjugated with PE, anti-human
Tim3 conjugated with BV421 (BioLegend), and anti-human CD4
conjugated with peridinin chlorophyll protein Cy5.5 (PerCP-
Cy5.5,BD Biosciences). Following incubation, the plated cells were
washed in washing buffer and then centrifuged, as detailed above,
and the supernatant was removed with this process being repeated
for an additional cycle. Afterward, cells were incubated in 1X Fix/
Perm buffer (eBioscience, Waltham, MA, USA) in a 4C refrigerator
for 45 min in the dark. Cells were pelleted by centrifugation and the
pellet resuspended in 1X Perm buffer (eBioscience) and centrifuged,
as described above. Cells were then incubated with 2% normal goat
serum (BioLegend), diluted with 1X Perm buffer (eBioscience), for
20 min on ice in the dark. Afterward, pellets were incubated with
anti-human Ki67 conjugated with APC (BioLegend) or mouse
IgG1 k isotype control conjugated with APC (BioLegend) on ice in
the dark for 30 min. After incubation, cells were washed twice with
1X Perm buffer (eBioscience) and then resuspended in wash buffer
and transferred to Falcon 12X75 5-mL round-bottom polystyrene
tubes (Corning) for flow cytometry. Cells were acquired using a
four-laser (BD Biosciences) LSRFortessa (BD), and 100,000 gated
events were collected for each sample. Analysis of results was per-
formed using BD FACSDiva software V.8.0.1 (BD Biosciences). Cells
were identified using their light scattering properties in the forward
and side scatter channels, and gates were positioned using single stain,
fluorescence minus one (FMO), and isotype controls.
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